
Global & Russia Cancer Therapeutics Market to 2031
Description
The cancer therapeutics market in Russia has been experiencing consistent growth, fueled by a rising incidence of cancer, enhancements in healthcare infrastructure, and increased awareness around early diagnosis and treatment. According to GLOBOCAN data, Russia saw over 600,000 new cancer cases in 2023, alongside approximately 300,000 cancer-related deaths. The most common cancers include lung, breast, colorectal, and prostate cancers, with lung cancer posing a major challenge due to high smoking prevalence. Factors such as an aging population, lifestyle risks like smoking and alcohol use, and environmental pollution contribute to the growing cancer burden. In 2022, around 640,000 new cancer cases were reported, with colorectal and breast cancers being the most frequently diagnosed. That year, cancer-related deaths reached roughly 310,000, including about 83,693 new colorectal cancer cases, which accounted for 13.2% of all registered cases—highlighting the substantial need for effective cancer therapies.
The market is also benefiting from the increasing availability of advanced treatments. Targeted therapies, immunotherapies, and personalized medicine are becoming more accessible, with immuno-oncology drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) leading the way. Additionally, the growing use of biosimilars offers more affordable alternatives to costly biologics, expanding access to treatment. Biosimilars for medications such as Herceptin and Rituxan are becoming increasingly popular in Russia. Partnerships with major global pharmaceutical companies, including Roche and Pfizer, have further supported the introduction of innovative cancer therapies, broadening treatment options for patients in the country.
The market is also benefiting from the increasing availability of advanced treatments. Targeted therapies, immunotherapies, and personalized medicine are becoming more accessible, with immuno-oncology drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) leading the way. Additionally, the growing use of biosimilars offers more affordable alternatives to costly biologics, expanding access to treatment. Biosimilars for medications such as Herceptin and Rituxan are becoming increasingly popular in Russia. Partnerships with major global pharmaceutical companies, including Roche and Pfizer, have further supported the introduction of innovative cancer therapies, broadening treatment options for patients in the country.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Russia Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Russia Cancer Therapeutics Market – Analysis
- 6.1 Russia Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Russia Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Russia Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Russia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Russia Cancer Therapeutics Market Analysis – by Indications
- 8.1 Russia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Russia Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Russia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Russia Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Russia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Russia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Russia Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.